Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Blood. 2014 Apr 24;123(17):2740-2. doi: 10.1182/blood-2014-02-553693.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Disease Progression
  • Disease-Free Survival
  • Humans
  • Leukemia / blood
  • Leukemia / diagnosis
  • Leukemia / drug therapy
  • Lymphoma, Follicular / blood
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / drug therapy*
  • Neoplastic Cells, Circulating / metabolism
  • Prognosis
  • Proportional Hazards Models
  • Rituximab
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab